The FDA does not approve dietary supplements before sale, but compliance is still mandatory. U.S. brands must verify ingredient status, cGMP manufacturing, labels, claims, adverse-event procedures, and recall readiness. Imported products may also require facility registration, a U.S. agent, and Foreign Supplier Verification Program controls.
Does the FDA Approve Dietary Supplements Before Sale?
No. Under the Dietary Supplement Health and Education Act of 1994, dietary supplements are regulated as a category of food rather than as drugs. FDA does not approve a finished supplement for safety, effectiveness, or labeling before it reaches consumers. The manufacturer and distributor are responsible for ensuring that the product is not adulterated or misbranded (FDA 101).
FDA can inspect facilities, examine imports, review notifications, issue warning letters, and act against violative products. An NDI notification is a premarket safety notification; a qualifying structure/function labeling claim notification is due after first marketing; and some health and nutrient-content claims require separate premarket authorization, petition, or notification pathways. None equals finished-product approval.
Who Is Responsible for Dietary Supplement Compliance?
Compliance is shared across the supply chain, but a contract cannot make regulatory risk disappear. The brand owner controls the product concept and marketing. The manufacturer controls production and many cGMP records. The U.S. importer has separate import-verification duties when a foreign supplier is involved.
| Party | Typical responsibilities | Documents to confirm |
|---|---|---|
| Brand owner or distributor | Formula approval, label and claims review, complaint intake, responsible-person duties, marketing controls | Final formula, approved artwork, claim substantiation file, complaint SOP, distribution records |
| Contract manufacturer | 21 CFR Part 111 controls, specifications, manufacturing and packaging records, testing, release or rejection | Master manufacturing record, batch record, specifications, test results, deviations, quality-unit release |
| U.S. importer | Applicable FSVP activities, supplier evaluation, import entry information, corrective action | FSVP records, supplier approval, verification results, corrective-action records |
| Foreign facility | FDA facility registration when required, U.S. agent, cGMP compliance, inspection readiness | Active registration, U.S. agent details, cGMP records, inspection and response records |
The exact allocation depends on the business model. Put responsibilities into the quality agreement before approving artwork or placing a production order. FDA has also stated that a firm may contract out operations but cannot contract out its ultimate responsibility for ensuring that a supplement it places into commerce is not adulterated because of cGMP failures (FDA warning-letter explanation).
The Main FDA Compliance Risks for Supplement Brands
1. The Product Does Not Qualify as a Dietary Supplement
Ingredients, dosage form, route, and intended use all affect classification. Disease-treatment claims can make a product a drug even if the package says “dietary supplement.” Review classification before finalizing the formula; this custom supplement formulation guide explains the development stages.
2. A New Dietary Ingredient Is Used Without the Required Notification
An NDI is generally a dietary ingredient not marketed in the United States before October 15, 1994. When required, the manufacturer or distributor must submit safety information at least 75 days before interstate marketing. Supplier sales history or marketplace availability is not proof of lawful status (FDA NDI process).
3. Manufacturing Does Not Meet 21 CFR Part 111
21 CFR Part 111 covers supplement manufacturing, packaging, labeling, and holding. A certificate of analysis alone is not enough: the system also needs specifications, component controls, batch records, investigations, complaint handling, and quality-unit review.
4. The Label Is Incomplete or Inaccurate
A label needs a statement of identity, net quantity, Supplement Facts, ingredient list, and business information. It must also match the final serving size and formula, including flavors, colors, capsule shells, and allergens. Keep approved copy and the packaging format under change control.
5. Marketing Crosses From Structure/Function Into Disease Claims
Qualifying structure/function claims in label or labeling need prior substantiation, the required disclaimer, and FDA notification no later than 30 days after first marketing. Disease-treatment claims can turn the product into a drug (FDA claim requirements).
The FTC also requires evidence before advertising is released and considers the full impression created by words, images, testimonials, and influencer content. Health-related claims generally need competent and reliable scientific evidence; FTC guidance says this will generally involve randomized, controlled human testing. A customer review becomes riskier when the brand republishes or adopts it (FTC guidance).
6. Serious Adverse Events Are Not Reported on Time
The responsible person is generally the manufacturer, packer, or distributor named on the label. Once the five minimum report elements are known, reports received through the label's domestic contact must be submitted within 15 business days; FDA recommends the same timing for other channels. Adverse-event records must be kept for six years (FDA guidance).
7. Imported Products Lack Required Registration or Verification
Required foreign facilities need FDA registration, biennial renewal, and a U.S. agent. U.S. importers may also have FSVP duties; for many finished supplements, verification focuses on dietary supplement cGMP compliance (FDA FSVP overview).
8. The Formula Contains Undeclared or Unlawful Substances
Undeclared drugs, unlawful colors, contamination, missing allergens, or a mismatch between label and composition can trigger detention or enforcement. Higher-risk categories need stronger supplier qualification and targeted testing.
FDA Dietary Supplement Label Checklist
| Label element | What to verify | Frequent problem |
|---|---|---|
| Statement of identity | Uses “dietary supplement” or an appropriate descriptive alternative | Product is presented like a conventional food or drug |
| Net quantity | Correct count, weight, or volume on the principal display panel | Confusion between serving size and package quantity |
| Supplement Facts | Serving size, servings, dietary ingredients, amounts, Daily Values where established | Formula or serving directions changed after panel approval |
| Other ingredients | Common or usual names in the required order | Flavor, color, shell, carrier, or processing component omitted |
| Business information | Name and place of business of manufacturer, packer, or distributor | Incomplete address or unclear “manufactured for” relationship |
| Claims and disclaimer | Claim category, substantiation, disclaimer placement, 30-day notification if applicable | Disease implication in product name, image, review, or social copy |
| Warnings and contact | Ingredient-specific warnings, major-allergen disclosure, domestic adverse-event contact | Generic warning copied from an unrelated formula |
Use the FDA labeling guide and current allergen information with the applicable regulations.
What cGMP Evidence Should a Brand Request?
Before production, review evidence that the manufacturer can control the exact product being ordered.
- Facility scope: Identify where manufacturing, packaging, labeling, testing, and release occur.
- Component controls: Confirm supplier qualification and ingredient-identity procedures.
- Specifications and testing: Review measurable criteria for components, packaging, and finished batches.
- Batch release: Confirm production records, investigations, results, and quality-unit approval.
- Change and recall controls: Require written change approval and reliable lot traceability.
Batch inconsistency is often a documentation and process-control problem, not just a final-test problem. See the related guide on batch-to-batch quality in imported supplements.
A Practical Pre-Launch Compliance Checklist
- Confirm product classification, ingredient status, safety, and any NDI requirement.
- Qualify the manufacturer, laboratories, suppliers, and importer where applicable.
- Approve the quality agreement, master record, specifications, and testing plan.
- Check the final label against the formula and serving directions.
- Substantiate every objective claim and complete required notifications.
- Assign foreign registration, U.S. agent, prior-notice, and FSVP duties.
- Define complaint intake, adverse-event reporting, and record retention.
- Test lot traceability and recall contacts before distribution.
Working With a Contract Supplement Manufacturer
A capable manufacturer can support formulation, testing, documentation, packaging, and production, but the brand should still retain its own regulatory review and written approvals. Start by defining who owns the formula, label copy, claims file, specifications, release decision, and post-market records.
Planning a U.S. Dietary Supplement Launch?
Review Honglan Health's custom packaging options when planning the label, container, and outer packaging for a supplement launch. Formula, dosage form, testing, packaging, and target-market responsibilities should be confirmed for each project before production.
Frequently Asked Questions
Does FDA registration mean a supplement is approved?
No. Facility registration is an administrative requirement and does not mean FDA has approved a product, formula, label, or claim.
Does the DSHEA disclaimer make any health claim legal?
No. The disclaimer is required for certain claims, but it does not protect a false, misleading, unsubstantiated, or disease-treatment claim.
When is a new dietary ingredient notification due?
When required, an NDIN must be submitted at least 75 days before the product is introduced or delivered for introduction into interstate commerce.
How quickly must a serious adverse event be reported?
Once the five minimum report elements are known, a report received through the domestic address or phone number on the label must be submitted within 15 business days. FDA recommends the same timing for other channels. Firms also need follow-up and six-year record-retention procedures.
Official Resources
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements.
- U.S. Food and Drug Administration. Dietary Supplements.
- U.S. Food and Drug Administration. Current Good Manufacturing Practices for Food and Dietary Supplements.
- U.S. Food and Drug Administration. Dietary Supplement Labeling Guide.
- U.S. Food and Drug Administration. Structure/Function Claim Notifications.
- U.S. Food and Drug Administration. New Dietary Ingredient Notification Process.
- U.S. Food and Drug Administration. Dietary Supplement Adverse Event Reporting and Recordkeeping.
- U.S. Food and Drug Administration. Foreign Supplier Verification Programs.
- Federal Trade Commission. Health Products Compliance Guidance.
